MORRISVILLE, N.C., October 9, 2023 — Premier Consulting, a business unit of Premier Research whose mission is to help the most innovative companies take their best ideas from concept to commercialization, is pleased to announce the appointment of William Bainbridge as Senior Director, Head of Commercial Strategy Solutions. Mr. Bainbridge has a range of therapeutic…
Expertise: Consulting 40 results
Consulting
Cheryl Silva
Consulting
John Thomas, M.Sc.
Consulting
Frank Keulen, M.Sc.
Consulting
Michael Edwards
Consulting
Abie Ekangaki, Ph.D.
The drug development process is a long journey, beginning with drug discovery, moving through nonclinical and clinical studies, and ultimately culminating in regulatory approval. With many steps in between, each as important as the next, multiple factors regarding development strategy and approach must be considered at the earliest stages. This blog post offers advice for…
One of the most common formulation issues that sponsors of new drug or biologic products face is the qualification of novel excipients. Although novel excipients can be a part of any new drug application (NDA) or biologics license application (BLA) development program, they seem to be more common with the 505(b)(2) pathway, since many companies…
Before the 2012 Food and Drug Administration (FDA) Nonprescription Safe Use Regulatory Expansion (NSURE) initiative, sponsors were transitioning prescription drugs (Rx) to over-the-counter (OTC). Streamlined access to effective treatments clearly benefits patients and payers. At the same time, easier access for consumers typically results in increased sales and profitability for pharma and biotech companies. As…
Morrisville, N.C., February 22, 2022 — Premier Research launched Premier Consulting today by consolidating two legacy brands within its portfolio — Regulatory Professionals, Inc. (RPI) and Camargo Pharmaceutical Services. Premier Consulting is a unified strategic product development and global regulatory consulting brand positioned for market leadership in support of emerging biotech and specialty pharma companies. The new…